The Aptamers Market is estimated to be valued at US$ 6265.49 Mn in 2023 and is expected to exhibit a CAGR of 18.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Aptamers are artificial single-stranded DNA or RNA oligonucleotides that are selected through an in vitro selection process called SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technique to bind to a broad range of target molecules with high affinity and specificity. Aptamers bind to their target ligands or cells through specific three-dimensional structures and bind to ligands with high affinity and specificity comparable to monoclonal antibodies. Aptamers can be created against a wide range of targets including small organic molecules, proteins, peptides, amino acids, antibiotics, nucleotides, drugs, and even whole cells and organisms. Some key advantages of aptamers include small size, highly specific target binding, better stability and storage conditions, and cost effectiveness. Aptamers are finding increasing applications in areas such as therapeutics, diagnostics, research and development.
Market Overview:
Aptamers are short, single-stranded DNA or RNA molecules that are selected using an in vitro selection process called SELEX (systematic evolution of ligands by exponential enrichment) to bind to target molecules such as proteins, peptides, toxins, and even whole cells with high affinity and specificity. Aptamers are finding increasing applications in areas such as drug discovery and development, diagnostics, research and other areas due to their high affinity and specificity for target molecules along with advantages such as smaller size, better stability and storage conditions, cost effectiveness compared to antibodies.
Market key trends:
One of the key trends driving the aptamers market is increasing applications in drug discovery and development. Aptamers have potential to complement or replace antibodies in diagnostics and therapeutics. Their small size allows deeper tissue penetration compared to antibodies. They can be engineered to bind to traditionally "undruggable" targets. Multi-valent aptamers show increased binding affinity and avidity. Aptamers also show promise as therapeutics in areas like oncology and ocular diseases. Companies are developing aptamer-based
Porter's Analysis
Threat of new entrants: The high R&D costs and intellectual property barriers pose significant threats to new entrants.
Bargaining power of buyers: The presence of numerous pharmaceutical companies means buyers have significant bargaining power over suppliers.
Bargaining power of suppliers: Suppliers like contract manufacturing organizations have moderate bargaining power due to their technical expertise.
Threat of new substitutes: Alternative drug discovery technologies like computational drug design pose a threat of substitution.
Competitive rivalry: The competition within aptamer therapeutics is intense given the large market size and lucrative opportunities.
SWOT Analysis
Strengths: Aptamers have advantages of high affinity and specificity for targets. They can be produced through cell-free processes at low costs.
Weaknesses: Aptamer stability and delivery remain challenges. Their production also requires specialized expertise and equipment.
Opportunities: Growing funding for R&D and increasing demand for personalized medicines offer opportunities. The technology is promising for diagnostics, biosensing and molecular imaging.
Threats: Stringent regulations associated with drug development pose threats. Reliance on few suppliers can impact continous supply.
Key Takeaways
The Global Aptamers Market Size is expected to witness high growth, exhibiting CAGR of 18.4% over the forecast period, due to increasing R&D investments by pharmaceutical companies for developing novel therapeutics.
Regionally, North America dominated the global market in 2023 owing to presence of major players and availability of funding. However, Asia Pacific is anticipated to be the fastest growing region due to growth in generic drugs market and rising biotechnology industry in countries like China and India.
Key players operating in the aptamers market are Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, NeoNeuro SAS, Aptagen LLC, Aptus Biotech S.L., AM Biotechnologies, LLC, Base Pair Biotechnologies, Vivonics Inc., CAGE Bio Inc., TAGCyx Biotechnologies Inc., AstraZeneca, GlyTech, Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies, Inc., SomaLogic Operating Co., Inc., Amsbio, and IVERIC bio, Inc. These companies are focusing on expanding their product portfolios and geographic footprint through mergers & acquisitions and collaborations with clinical research organizations.
Get More Insights Here
https://www.newswirestats.com/aptamers-market-share-size-forecast-outlook-2023-2030/
